Tiny Redx slammed after first patient is hit by adverse events, forcing a halt to cancer drug study
The microcap biotech Redx has lurched from a financial pickle straight into a damaging safety issue with its lead drug.
The UK biotech has suspended …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
